ESR1 and cancer: Our proposed genomic assay, ImPrint, captures more comprehensive immune activity status to permit more effective selection of IO-sensitive ER+HER2– cancers, as the ImPrint+ cancers have a 75% pCR rate with neoadjuvant IO therapy.